Molecular characterisation of resistantMycobacterium tuberculosisisolates from Dr George Mukhari Hospital, Pretoria, South Africa
| Autor: | B. E. de Villiers, Lawrence C. Obi, P.P. Sein, Pascal O. Bessong, A.A. Hoosen, Maphoshane Nchabeleng, Ezekiel Green, Tomas Letsoalo |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Drug supply
medicine.medical_specialty biology Epidemiology business.industry Isoniazid Dermatology Drug resistance Pyrazinamide bacterial infections and mycoses biology.organism_classification Mycobacterium tuberculosis Infectious Diseases Streptomycin Internal medicine Immunology medicine business Ethambutol Rifampicin medicine.drug |
| Zdroj: | Southern African Journal of Epidemiology and Infection. 23:11-14 |
| ISSN: | 1015-8782 |
| DOI: | 10.1080/10158782.2008.11441316 |
| Popis: | Control of the TB epidemic depends on adequate treatment. Although chemotherapy has been an effective tool in the management and control of TB previously, development of drug resistance poses a serious challenge in the control of the disease. Potential factors contributing to development of drug resistance include inadequate treatment regimens prescribed by health staff, poor case holding of TB patients, poor drug supply, poor drug quality, patient error in following prescribed regimens and misuse of TB drugs including non-compliance.5 TB is treated using three front line agents, isoniazid (INH), rifampicin (RIF) and pyrazinamide (PZA), and one of the second line anti-TB drugs, streptomycin (SM) and ethambutol (EMB).6 Multidrug-resistant TB (MDR-TB), defined as resistance to at least INH and RIF with or without resistance to other drugs, has been reported in different parts of the world.7 However, the |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|